Novartis would like artificial intelligence (AI) and data science to power decision-making “everywhere relevant” in the company. In an interview with Scrip, CEO Vas Narasimhan outlines how things have already shaped up along the company’s digital transformation journey and where it’s headed.
One of the notable mileposts is that all 550 of the firm’s clinical trials are now overseen from a central...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://insights.citeline.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)

